
At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. By safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today.
Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early.
By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.
Location: United States, Massachusetts, Cambridge
Member count: 51-200
Total raised: $183M
Founded date: 2009
Investors 8
Funding Rounds 6
Date | Series | Amount | Investors | Deal News |
23.03.2021 | - | $80M | - | oaoa.com/n... |
02.04.2019 | Series D | $40M | - | finsmes.co... |
21.12.2017 | Series C | $30M | Arix Biosc... | arixbiosci... |
29.09.2016 | - | $8M | - | vcnewsdail... |
05.03.2015 | Series B | $21M | - | vcnewsdail... |
15.08.2014 | - | $4M | - | medcitynew... |
Mentions in press and media 33
Date | Title | Description | Source |
03.05.2023 | WCVB Channel 5 Chronicle Reporter and Producer Nicole Estaph... | BOSTON (PRWEB) May 03, 2023 The Melanoma Research Foundation (MRF) is thrilled to announce that WCV... | prweb.com/... |
22.11.2022 | Aura, the frame and photo startup, raises $26M as it nears 3... | Aura, a startup founded by early Twitter employees that makes digital frames and photo sharing apps ... | techcrunch... |
07.11.2022 | Prevent Blindness Names Jim McGrann Chair of its Board of Di... | Jim McGrann, CEO of Professional Eyecare Associates of America (PECAA), named Chair of the Prevent B... | prweb.com/... |
03.11.2021 | Ysios Capital anuncia la salida a bolsa en el NASDAQ de su c... | 03/11/2021 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PART... | webcapital... |
03.11.2021 | Ysios Capital’s portfolio company Aura Biosciences prices IP... | 03/11/2021 Press release YSIOS CAPITAL’S PORTFOLIO COMPANY AURA BIOSCIENCES PRICES IPO ON NASDAQ. ... | webcapital... |
23.03.2021 | Aura Biosciences picks up $80M | Aura Biosciences has raised $80 million in a round co-led by Matrix Capital Management and Surveyor ... | pitchbook.... |
22.03.2021 | Aura Biosciences announces oversubscribed $80 million financ... | 22/03/2021 Press release AURA BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $80M FINANCING. Proceeds to Su... | webcapital... |
22.03.2021 | Aura Biosciences Scores $80M in Financing | CAMBRIDGE, MA, Aura Biosciences announced the closing of an oversubscribed $80 million financing l... | vcnewsdail... |
22.03.2021 | Aura Biosciences Announces Oversubscribed $80 Million Financ... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- Aura Biosciences, a clinical-stage oncology compa... | oaoa.com/n... |
22.03.2021 | Aura Biosciences cierra una ronda de $80M liderada por Matri... | 22/03/2021 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE $80 MILLONES DE S... | webcapital... |
Show more